VADASTUXIMAB TALIRINE
UNII T13V17U431

Substance Identification & Data

This profile provides standardized clinical and technical data for Vadastuximab Talirine, uniquely identified by the FDA Unique Ingredient Identifier (UNII) T13V17U431.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 1436390-64-5 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

T13V17U431

CAS Registry Number

1436390-64-5

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

VADASTUXIMAB TALIRINE

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C111039

National Cancer Institute reference terminology for clinical and research data.

INN ID

9983

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

CD-154

Identifier assigned by the United States Adopted Names Council.

Substance Type

protein

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Vadastuximab Talirine. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

VADASTUXIMAB TALIRINE

Common Names & Synonyms

VADASTUXIMAB TALIRINE [INN]

VADASTUXIMAB TALIRINE [USAN]

VADASTUXIMAB TALIRINE [WHO-DD]

Systematic Nomenclature

IMMUNOGLOBULIN G1, ANTI-(HUMAN SIALIC ACID-BINDING IMMUNOGLOBULIN-LIKE LECTIN 3) (HUMAN-MUS MUSCULUS MONOCLONAL H2H12EC HEAVY CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL H2H12EC LIGHT CHAIN, DIMER, BIS(THIOETHER) WITH N-(6-(3-MERCAPTO-2,5-DIOXO-1-PYRROLIDINYL)-1-OXOHEXYL)-L-VALYL-N-(4-((11AS)-8-(3-(((11AS)-5,11A-DIHYDRO-7-METHOXY-2-(4-METHOXYPHENYL)-5-OXO-1H-PYRROLO(2,1-C)(1,4)BENZODIAZEPIN-8-YL)OXY)PROPOXY)-5,11A-DIHYDRO-7-METHOXY-5-OXO-1H-PYRROLO(2,1-C)(1,4)BENZODIAZEPIN-2-YL)PHENYL)-L-ALANINAMIDE

SYS

IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS CD33 (SIALIC ACID BINDING LG-LIKE LECTIN 3, SIGLEC3, SIGLEC-3, GP67, P67)), CHIMERIC MONOCLONAL ANTIBODY CONJUGATED TO THE PYRROLOBENZODIAZEPINE (PDB) DIMER SGD-1882 GAMMA1 HEAVY CHAIN (1-447) (MUS MUSCULUS VH (IGHV1-85*01 -(IGHD)-IGHJ4*01) (8.8.10) (1 -117) -HOMO SAPIENS IGHG1*01, G1M17,1 (CH1 (118-215), HINGE (216-230), CH2 S3>C (239) (231-340), CH3 (341-445), CHS (446-447)) (118-447)), (220-214')-DISULFIDE WITH KAPPA LIGHT CHAIN (1'-214') (MUS MUSCULUS V-KAPPA (IGKV14-111*01 -HOMO SAPIENS IGKJ4*01) (6.3.9) (1'-107') -HOMO SAPIENS IGKC*01, KM3 (108'-214')) DIMER (226-226'':229-229'')-BISDISULFIDE CONJUGATED, ON TWO SITE-SPECIFIC DRUG ATTACHMENT ENGINEERED CYSTEINES (C239, C239''), TO A MAXIMUM OF 2 PYRROLOBENZODIAZEPINE (PDB) DIMERS SGD-1882, EACH VIA A CLEAVABLE (VALINE-ALANINE DIPEPTIDE AS CATHEPSINE B CLEAVAGE SITE) MALEIMIDOCAPROYL TYPE LINKER

SYS